Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations - Seite 3

About EndoscopyNow

The EndoscopyNow digital platform is a specialty-agnostic mobile application presenting news, clinical data, procedural insights, and product information to the global GI endoscopy community. To learn more about EndoscopyNow, visit www.EndoscopyNow.com.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

1. Esophageal Cancer Action Network; https://ecan.org/; accessed 4/10/24

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410800879/en/

The Castle Biosciences Stock at the time of publication of the news with a fall of -5,15 % to 20,43USD on Nasdaq stock exchange (10. April 2024, 22:30 Uhr).